Hims & Hers Health: Roller Coaster Gift
Update - Nov. 13, 2025 Hims & Hers Health has slipped below key support around $40. The online health and wellness platform is getting incredibly cheap at just 3x '26 sales estimates of $2.8 billion. The company even just launched Labs, a preventative care lab test. Original article posted on Oct. 20 Hims & Hers Health launched menopause and low testosterone products in the last month, expanding its addressable market and supporting its $6.5 billion 2030 revenue target. Recent product launches, including at-home lab testing, are expected to boost ARPU and drive significant revenue growth for HIMS in coming years. The stock market over reacted to planned stock sells by the CEO. Current weakness in HIMS shares presents a buying opportunity, with the stock trading at just 4x projected 2026 sales and robust long-term potential. Looking for a portfolio of ideas like this one? Members of Out Fox The Street get exclusive access to our subscriber-only portfolios. Learn More ...